Genome Analysis Across Populations in Inflammatory Bowel Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorMount Sinai Hospital, Canada
About this trial
Objective:
To use clinical, genetic and genome analysis to better understand and define the genetic and environmental factors that contribute to IBD within affected populations.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Subjects: diagnosed with Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis, IBD-undetermined)
Available medical records to confirm IBD diagnosis (Crohn's disease, Ulcerative colitis, IBD undetermined (IBD-U))
Healthy controls: no personal history of IBD, no family history of IBD, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss
Any age
Disqualifiers
None
Trial population
IBD or Healthy controls (non-IBD)
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Blood or saliva sample collection
GeneticBlood or saliva sample \& clinical data collection
Treatment groups
150 Participants
are divided into 2 treatment groupsGroup A: IBD Subjects1 intervention
Group B: Controls1 intervention
Trial outcomes
Primary outcomes
1
Genomics studies across populations
Whole Exome Sequencing (+/- other sequencing) is planned
Time frame
2022-2027Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Mount Sinai Hospital, Canada
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Source ClinicalTrials.gov